Class summary at a glance.

Every drug in the CD20-directed Cytolytic Antibody class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class: 8tracked in Part D
CY24 Part D spend: $1.46Bcombined across class
Total Rx claims: 124K29K unique beneficiaries
Generic mfrs (active): 0across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard

Ofatumumab

Brand: ARZERRA · 98K Part D claims (CY24) · 15K beneficiaries · First FDA approval: 2009-10-26

Brand-only (no generics) 236 plans require PA

Low NADAC$24459.32

→

Avg plan cost$24459.32

Part D spend $975.4M 1× spread, current vs floor

Class share

67%

of class CY24 spend

View profile →

Ocrelizumab

Brand: OCREVUS · 8K Part D claims (CY24) · 6K beneficiaries · First FDA approval: 2017-03-28

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend $319.4M

Class share

22%

of class CY24 spend

View profile →

Rituximab

Brand: Rituxan · 5K Part D claims (CY24) · 3K beneficiaries · First FDA approval: 1997-11-26

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend $61.6M

Class share

of class CY24 spend

View profile →

Rituximab-Pvvr

Brand: Ruxience · 5K Part D claims (CY24) · 2K beneficiaries · First FDA approval: 2020-01-23

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend $42.1M

Class share

of class CY24 spend

View profile →

Rituximab-Abbs

Brand: Truxima · 4K Part D claims (CY24) · 2K beneficiaries · First FDA approval: 2020-05-04

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend $36.2M

Class share

of class CY24 spend

View profile →

Obinutuzumab

Brand: Gazyva · 1K Part D claims (CY24) · 395 beneficiaries · First FDA approval: 2013-11-01

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend $15.0M

Class share

of class CY24 spend

View profile →

Rituximab-Arrx

Brand: Riabni · 2K Part D claims (CY24) · 596 beneficiaries · First FDA approval: 2021-01-06

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend $11.6M

Class share

of class CY24 spend

View profile →

Ublituximab

Brand: BRIUMVI · — Part D claims (CY24) · First FDA approval: 2022-12-28

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

of class CY24 spend

View profile →

Class summary at a glance.

Every drug in this class, ranked by Part D spend.

Related questions.